TrialThe oncologist2025

SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma.

Jorien B E Janssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.